Avacta and AI10 May 2023 08:54
This morning buy prints going through,picking up yesterday’s “ sales print “.
Meanwhile out on Bloomberg : “ AI Drug Discovery is a $50 Billion oppertunity for Big Pharma”.
Stand by for ASCO coming up and AI.
AI, including its best-known branch of research, machine learning, has significant potential to enable precision oncology well beyond relatively well-known pattern recognition applications, such as the supervised classification of single-source omics or imaging datasets.
It will be recognised by the market much faster now and by the majors ( as Novartis has pointed out, they are making job cuts in certain areas, while focussing on “new Medicine”)the enormous potential Precision oncology and the likes of Avacta will have !